References
- Nathan JA, Sharples LD, Exley AR, Sivasothy P, Wallwork J. The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency. J Heart Lung Transplant. 2005;24(10):1517–1521. doi:10.1016/j.healun.2004.11.013
- Barnes S, Kotecha S, Douglass JA, et al. Evolving practice: x-linked agammaglobulinemia and lung transplantation. Am J Transplant. 2015;15(4):1110–1113. doi:10.1111/ajt.13084
- Lay C, Law N, Holm AM, Benden C, Aslam S. Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: an ISHLT registry‒based analysis. J Heart Lung Transplant. 2019;38(5):545–552. doi:10.1016/j.healun.2019.01.1306
- Coiffard B, Prud’Homme E, Hraiech S, et al. Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation. BMC Pulm Med. 2020;20(1):109. doi:10.1186/s12890-020-1151-9
- Aranaga C, Pantoja LD, Martínez EA, Falco A. Phage therapy in the era of multidrug resistance in bacteria: a systematic review. Int J Mol Sci. 2022;23(9):4577. doi:10.3390/ijms23094577
- Nordstrom HR, Evans DR, Finney AG, et al. Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates. iScience. 2022;25(6):104372. doi:10.1016/j.isci.2022.104372
- Aslam S, Courtwright AM, Koval C, et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019;19(9):2631–2639. doi:10.1111/ajt.15503
- Syed MN, Kutac C, Miller JM, et al. Risk factors of Pneumonia in primary antibody deficiency patients receiving immunoglobulin therapy: data from the US Immunodeficiency Network (USIDNET). J Clin Immunol. 2022;42(7):1545–1552. doi:10.1007/s10875-022-01317-2
- Huwyler C, Lin SY, Liang J. Primary immunodeficiency and rhinosinusitis. Immunol Allergy Clin North Am. 2020;40(2):233–249. doi:10.1016/j.iac.2019.12.003
- Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185. doi:10.3389/fimmu.2013.00185
- Nierhaus A, Berlot G, Kindgen-Milles D, Müller E, Girardis M. Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis. Ann Intensive Care. 2020;10(1):132. doi:10.1186/s13613-020-00740-1
- Borleffs JCC, Schellekens JF, Brouwer E, Rozenberg-Arska M. Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with PersistentCampylobacter jejuni infection. Eur J Clin Microbiol Infect Dis. 1993;12(10):772–775. doi:10.1007/BF02098467
- Langereis JD, van der Flier M, de Jonge MI. Limited innovations after more than 65 years of immunoglobulin replacement therapy: potential of IgA- and IgM-enriched formulations to prevent bacterial respiratory tract infections. Front Immunol. 2018;9:1925. doi:10.3389/fimmu.2018.01925
- Parulekar AD, Kao CC. Detection, classification, and management of rejection after lung transplantation. J Thorac Dis. 2019;11(S14):S1732–S1739. doi:10.21037/jtd.2019.03.83
- Maddocks S, Fabijan AP, Ho J, et al. Bacteriophage therapy of ventilator-associated Pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019;200(9):1179–1181.
- Marongiu L, Burkard M, Lauer UM, Hoelzle LE, Venturelli S. Reassessment of historical clinical trials supports the effectiveness of phage therapy. Clin Microbiol Rev. 2022;35(4):e0006222. doi:10.1128/cmr.00062-22
- Lebeaux D, Merabishvili M, Caudron E, et al. A case of phage therapy against pandrug-resistant achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses. 2021;13(1):60. doi:10.3390/v13010060
- Guillon A, Pardessus J, L’Hostis G, et al. Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation. Br J Pharmacol. 2021;178(18):3829–3842. doi:10.1111/bph.15526